Celldex (CLDX) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Celldex (CLDX) Tops Q2 EPS by 4c

Celldex Reports Second Quarter 2017 Results

August 8, 2017 4:01 PM EDT

HAMPTON, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported business and financial highlights for the second quarter ended June 30, 2017.

"In the second quarter, we continued to see strong physician enthusiasm for our Phase 2 METRIC study of glembatumumab vedotin in triple negative breast cancer and recently met our target enrollment of 300 patients, said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. We expect enrollment will be formally closed by the end of September to allow all patients currently in the screening queue the... More